Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus
1 other identifier
observational
N/A
1 country
1
Brief Summary
Systemic lupus erythematosus is an often devastating autoimmune disease which affects 1 in 2,000 women in the United States. Recently, several research laboratories have reported that a protein, named CD40-ligand (CD154), is overexpressed by a subset of white blood cells, called lymphocytes, in patients with lupus. Expression of CD154 appears critical to the generation of antibodies that cause disease in lupus. Blocking CD154 interactions in the immune system has been shown to decrease disease activity in animal models of lupus. We propose to study the regulation of CD154 in patients with lupus in hopes of inhibiting its abnormal and deleterious expression.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 16, 2001
CompletedFirst Posted
Study publicly available on registry
January 18, 2001
CompletedJune 24, 2005
December 1, 2003
January 16, 2001
June 23, 2005
Conditions
Eligibility Criteria
You may qualify if:
- A diagnosis of systemic lupus erythematosus
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Sponsor Type
- NIH
Study Record Dates
First Submitted
January 16, 2001
First Posted
January 18, 2001
Last Updated
June 24, 2005
Record last verified: 2003-12